URGN — UroGen Pharma Ltd.

UroGen Pharma Ltd. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $109.8 million for the year ended December 31, 2025, up 21% from $90.4 million in 2024.
• Zysturi Revenue: $15.8 million for 2025, with Q4 revenue of $14 million.
• Jelmyto Revenue: $94 million for 2025, reflecting continued demand growth.
• Net Loss: $153.5 million, or $3.19 per share, compared to a net loss of $126.9 million, or $2.96 per share, in 2024.
• Cash Position: $120.5 million in cash, cash equivalents, and marketable securities as of December 31, 2025.
• Debt Refinancing: Entered into a $250 million term loan facility with Pharma Advisors, providing additional capital and reducing interest costs.

2. Strategic Updates and Business Highlights

• Zysturi Launch: Focus on the commercial launch of Zysturi for recurrent, low-grade, intermediate-risk non-muscle invasive bladder cancer, with a permanent J code effective January 1, 2026, facilitating patient access.
• Pipeline Development:
  • UGN-103 (next-generation formulation) shows promising Phase 3 results, with an NDA submission planned for 2026 and potential FDA approval in 2027.
  • UGN-104 is progressing through Phase 3 trials.
  • UGN-501 (next-generation oncolytic virus) is in IND-enabling studies, with a Phase 1 trial expected in 2026.
• Commercial Strategy: Focus on building a strong foundation for Zysturi's adoption, including expanding the commercial team and establishing reimbursement pathways.

3. Forward Guidance and Outlook

• Jelmyto Revenue Guidance: Expected net product revenue for 2026 is projected to be between $97 million and $101 million, reflecting a 3% to 7% growth over 2025.
• Operating Expenses: Anticipated to be between $240 million and $250 million for 2026, driven by increased salesforce costs and share-based compensation.
• Zysturi Sales Guidance: No formal guidance provided for Zysturi as it is still in the early launch phase; future guidance may be considered after two quarters post-J code implementation.

4. Bad News, Challenges, or Points of Concern

• Net Loss Increase: The significant increase in net loss raises concerns about the company's path to profitability.
• Market Adoption Risks: While early indicators for Zysturi are positive, the company faces challenges in achieving widespread adoption and ensuring reimbursement processes are smooth.
• Competitive Landscape: The evolving treatment landscape for bladder cancer may pose competitive pressures, especially as new therapies emerge.

5. Notable Q&A Insights

• Patient Enrollment Forms: Early indicators show that Zysturi is outperforming Jelmyto in terms of patient enrollment forms and prescriber engagement since the J code became effective.
• Prescriber Trends: There is steady growth in both new and repeat prescribers for Zysturi, with positive feedback regarding its ease of use and patient acceptance.
• Life Cycle Management: Plans for UGN-103 include exploring its use in adjuvant settings, with potential trials expected in 2026. The company aims to transition from Zysturi to UGN-103 efficiently to minimize confusion among physicians and patients.
• Community vs. Academic Adoption: The adoption mix for Zysturi is shifting towards community settings, which may enhance long-term growth as these practices gain experience with the product.

Overall, UroGen Pharma is optimistic about its growth trajectory, particularly with Zysturi, while also navigating the challenges of market adoption and financial sustainability.